Atopic Dermatitis

Ruxolitinib cream offers an effective nonsteroidal treatment for mild to moderate atopic dermatitis, with proven efficacy and safety for sensitive skin areas.

The 9-month interim results of the TRACE study were presented at EADV 2024, highlighting tralokinumab’s efficacy in a subset of patients with eczema impacting the head and neck areas.

The DELTA trial results on delgocitinib cream as a topical option for CHE were presented at the EADV Congress 2024.

Temtokibart showed similar efficacy to dupilumab in treating moderate-to-severe atopic dermatitis, with faster skin hydration improvements in a phase 2a trial.

These new data on treatment of atopic dermatitis and prurigo nodularis were presented by Galderma at the European Academy of Dermatology & Venereology Congress.

These new findings were released by Eli Lilly and presented at the European Academy of Dermatology & Venereology Congress.

The FDA decision to accept the new drug application for delgocitinib cream is also occurring alongside the drug’s acceptance by the European Commission.

After his review on recent literature, Zirwas’s Maui Derm NP+PA Fall interview featured a discussion about the biggest unmet needs among patients.

Leo Pharma announced the availability of a single-dose autoinjector of tralokinumab for moderate-to-severe atopic dermatitis, approved by the FDA in June 2024.

These poster data highlight that atopic dermatitis treatment may be suboptimal in certain patients, demonstrating the necessity of additional effective therapy options.

Nemolizumab shows early and sustained benefits in reducing itch and sleep disturbance in moderate-to-severe atopic dermatitis, per ARCADIA data.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

This is an overview of our upcoming Maui Derm NP+PA Fall 2024 Program conference coverage.

Eli Lilly’s announcement of the lebrikizumab-lbkz approval for patients 12 years of age and older follows positive findings from the ADvocate 1, ADvocate 2, and ADhere studies.

Multiple biomarkers and clinical background factors were linked to improved clinical outcomes after dupilumab therapy for AD.

In this analysis, an increased risk of allergy and eczema was associated with bread and thiamine intake increases during pregnancy.

In this survey, investigators sought to develop a definition for eczema flare which was patient-centered and based upon consensus.

These data may provide invaluable insights, given the lack of reliable methods for identifying newborns with increased risk of developing eczema.

These findings resulted from a systematic literature review highlighting the impact of stigma and lack of support on self-image for patients with eczema, psoriasis, HS, and other conditions.

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.

After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.

These data were presented at the European Society of Contact Dermatitis congress, with findings drawn from the CHECK and RWEAL studies on chronic hand eczema.

The panel provides comprehensive insights on treating atopic dermatitis and how recent advances have elevated standard-of-care treatment practices in dermatology practices.

These data suggest the necessity of caution when clinicians treat select patient groups with dupilumab for atopic dermatitis.

These data are encouraging for tralokinumab, though additional observational research with more individuals with atopic dermatitis or longer follow-up periods may be necessary.

These data reaffirm NB-UVB phototherapy’s use in treating patients with atopic dermatitis and psoriasis, suggesting improvement in patient-reported outcome measures.

This analysis was conducted to evaluate the efficacy and safety results of AIT for patients with house dust mite allergies.

A panel of experts on atopic dermatitis discuss how patient preferences are taken into account when choosing between available treatments.

Jonathan Silverberg, MD, PhD, MPH, offers insights on the role of patient-reported outcomes in informing treatment decisions for patients with atopic dermatitis.